New Product Launch: 3 Target Genes for SARS CoV-2 PCR Testing

Company news

Based on the fluorescent PCR technology, designed to detect and a total of 3 target genes including ORF1a/b, N gene and E gene, Bioperfectus COVID-19 Coronavirus (ORF1ab/N/E) Real Time PCR Kit is a multiplex, single-well/vessel run assay.



Multiplex real-time PCR detect 3 targets specific for SARS-CoV-2

Internal control ensures the whole process reliability

Better performance makes the result more accurate

More efficient: 96 tests in 72 minutes (on an instrument)

Suitable for more mainstream instrument



Target region: ORF1a/b, N gene and E gene

Limit of detection: 200 copies/mL

Sample input volume: 5μL

Sample type: Nasopharyngeal swab and sputum


Learn more about the product, please click here.

Inquiry about the product, please send email to, media cooperation & exhibition opportunity, please email to 


Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.


Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.


Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).